Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
accreted, acknowledgement, affiliated, arm, assessor, BCF, bicarbonate, bid, blended, bond, Brent, captioned, Carlo, clause, Clevlen, complaint, consecutive, contrast, Cornerstone, criterion, daily, Deferral, District, DMC, domestic, duodenum, easy, entry, float, Footnote, freestanding, Furse, gastric, grace, halal, herewith, hypothesized, immunological, implied, ineligible, Instruction, instrument, issuable, kosher, lessee, liberal, mandatory, margin, marked, Master, mesangium, mezzanine, middle, missed, mITT, modifiy, Monte, multiplied, narrowly, NOL, Northern, older, paradigm, paragraph, partnership, pattern, PCR, peer, Pennington, penny, Pharmacologic, Pleasanton, predefined, proceed, proceeding, proinflammatory, promulgated, qualification, quantified, redeem, redeemable, redemption, relief, residual, retrospective, Rock, ROU, Secretary, Shanahan, shareholder, tendency, timeline, timepoint, titration, Tranche, transition, twelve, unanimously, unattractive, underwriter, underwriting, unspecified, usability, venture, vigorously, VWAP, Wainwright, wholly, William
Removed:
acquired, activated, affinity, aim, alteration, American, AMG, antagonist, atacicept, attained, auto, autoantibody, background, Benlysta, brain, breath, cardiovascular, College, Conference, convenient, corroborate, corticosteroid, Diego, differentiate, differentiated, diversification, DNA, DSMB, dual, durable, economic, emerged, emerging, enhanced, enriched, evident, exceeding, excluding, exhibited, exploration, expression, fatigue, feedback, figure, flare, flexibility, focusing, Furie, gamma, Genome, GlaxoSmithKline, Golima, graph, GSK, headache, heart, hematological, ImmuPharma, improved, inappropriate, inflammatory, injector, inside, Instance, League, lieu, linear, Linkbase, lt, lung, Lupuzor, Madrid, managing, memory, men, Merck, mice, midcap, milatuzumab, modulation, monoclonal, nadir, nausea, neurologic, neutralization, noncancellable, numerically, opened, overwhelming, pathway, PGA, pharmacokinetic, phosphodiesterase, platform, plc, pledge, plotted, pooled, ran, randomization, randomize, rash, rated, refinancing, regimen, resolution, resolved, rheumatology, Richard, sample, San, Sanford, Schema, score, selective, SELENA, Separately, Serono, serving, sex, show, significance, sirukumab, skin, SLEDAI, sodium, SRI, steroid, stopping, stringent, subgroup, sudden, summarizing, suppression, sustain, swelling, swollen, syringe, tabalumab, Taxonomy, transgenic, transiently, translate, transplantation, typical, ulceration, understood, undesignated, unrealized, utilized, variant, vesting, white, women, worsening, XBRL, Zweifach
Filing tables
Filing exhibits
Related press release
ANTH similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
Anthera Pharmaceuticals, Inc.
Hayward, California
We hereby consent to the incorporation by reference in the Registration Statements on Form S--3 (No. 333-175095, No. 333-179043, No. 333-187771, No. 333-187780 and No. 333-210166) and Form S--8 (No. 333-165714, No. 333-168970, 333-172100, No. 333-180144, No. 333-186679 No. 333-196740 and No. 333-213956) of Anthera Pharmaceuticals, Inc. of our reports dated March 16, 2017, relating to the consolidated financial statements and the effectiveness of Anthera Pharmaceuticals, Inc.’s internal controls over financial reporting, which appear in this Form 10-K. Our report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.
San Jose, California
March 16, 2017